Studies concerning peroxisomal β-oxidation have mainly been performed using radiolabelled fatty acids, after which the end products, 14 CO 2 and water-soluble radiolabelled products were measured (Wanders et al 1995) . These studies only enable the investigation of a complete β-oxidation cycle and do not distinguish between the individual steps of β-oxidation. We have developed a method for investigation of the first two steps of peroxisomal β-oxidation of pristanic acid in human liver. After incubation of human liver homogenates with pristanic acid or pristanoyl-CoA, the intermediates formed were hydrolysed to give their free acids, derivatized, and quantified by stable-isotope dilution gas chromatography -mass fragmentography with negative chemical ionization. The applicability of the method described in this paper is demonstrated by showing the deficient oxidation of 2,3-pristanic acid to pristenic acid and 3-hydroxypristanic acid in liver from a Zellweger (McKusick 214100) patient.
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MATERIALS AND METHODS

Preparation of human liver homogenates:
Pieces of human liver from controls and Zellweger patients were stored at − 70°C and thawed in a medium containing 250mmol/L mannitol, 5mmol/L Mops -NaOH and 1mmol/L EDTA (pH 7.4). Following homogenization in a glass homogenizer, the whole homogenates were used for enzyme studies.
Incubation conditions:
The incubation mixture for studying pristanic acid metabolism contained, besides homogenized human liver (1mg protein): 150mmol/L KCl, 50mmol/L Hepes -NaOH, 2mmol/L K 3 PO 4 and 50 µmol/L of the substrate (pristanic acid or pristanoyl-CoA). To some incubations the following cofactors were added: 3mmol/L MgCl 2 , 2mmol/L ATP and 0.2mmol/L coenzyme A. The final pH was 7.4. Reactions were allowed to proceed for 60min at 37°C and were terminated by adding HCl (final concentration 0.33mol/L).
Pristanic acid, 2,3-pristenic acid, 3-hydroxypristanic, [2-methyl-2 H 3 ]pristanic acid, [2-methyl-2 H 3 ]pristenic acid and 3-hydroxy [2-methyl-2 H 3 ]pristanic acid were synthesized in the Free University Hospital Amsterdam. Pristanoyl-CoA was synthesized from pristanic acid using a previously described method (Rasmussen et al 1990) .
Pristanic acid and 2,3-pristenic acid were measured as their pentafluorobenzyl derivatives and 3-hydroxypristanic acid was measured as its pentafluorobenzyl-acetyl derivative by stable-isotope dilution gas chromatography-mass fragmentography with negative chemical ionization. The derivatization procedure and analytical conditions were essentially as described before (Wanders et al 1994) . Measurements were performed in the selected-ion monitoring (SIM) mode, measuring the fragments with m/z values 295 and 298 for pristenic acid and its internal standard and m/z 355 and 358 for 3-hydroxypristanic acid and its internal standard, respectively.
RESULTS AND DISCUSSION
When control human liver was incubated with pristanic acid, in the absence of ATP, Mg 2+ and coenzyme A, no formation of 2,3-pristenic acid and 3-hydroxypristanic acid was observed. However, when ATP, Mg 2+ and coenzyme A were added to the incubation mixture, formation of 2,3-pristenic acid amounted to about 170pmol/min per mg protein, whereas 3-hydroxypristanic acid was formed in lower amounts (2.4pmol/min per mg protein). Figure 1 shows that formation of pristenic acid and 3-hydroxypristanic acid is linear with time for at least 80min.
The necessity for coenzyme A in the incubation mixture implies that pristanic acid first Figure 1 Formation of pristenic acid and 3-hydroxypristanic acid from pristanic acid in liver homogenates from a control and a Zellweger patient, in the presence of ATP, Mg 2+ and coenzyme A needs to be activated to pristanoyl-CoA before oxidation can occur. This was further investigated by using pristanoyl-CoA instead of pristanic acid as substrate. Higher rates of formation of intermediates were observed (210pmol/min per mg protein for pristenic acid and 4.5pmol/min per mg protein for 3-hydroxypristanic acid). As expected, when pristanoyl-CoA was used as substrate, the formation of intermediates was not influenced by added coenzyme A. Figure 1 shows that formation of 2,3-pristenic acid and 3-hydroxypristanic acid was deficient in a liver homogenate from a Zellweger patient, irrespective of whether pristanic acid or pristanoyl-CoA was used as substrate.
The results described in this paper demonstrate the existence of the β -oxidation intermediates of pristanic acid: 2,3-pristenic acid and 3-hydroxypristanic acid. Furthermore, it is shown that activation of free pristanic acid to pristanoyl-CoA is essential for degradation of this compound.
In liver from a Zellweger patient, neither 2,3-pristenic acid nor 3-hydroxypristanic acid was found after incubation with pristanic acid or pristanoyl-CoA, which is in accordance with the elevated plasma levels of pristanic acid found in these patients (Ten Brink et al 1992) and the deficiency of pristanoyl-CoA oxidase which has been reported before (Wanders et al 1990) .
